Use of a Highly Concentrated Intranasal Spray Formulation of Desmopressin in Persons with Congenital Bleeding Disorders

Lusher, Jeanne M.; Miller, Erin; Wiseman, Carol; Draughn, Madonna; Warrier, Indira

doi:10.1007/978-1-4615-2922-4_35

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results have been documented by Lusher et al [29], and by Seremetis and Aledort [30] and Rose and Aledort [31]. Lusher et al [29] found that the BT was shortened in 67 and 71 % of vWD subjects following IN spray DDAVP, while Seremetis and Aledort [30] reported correc tion of the BT in 5 of 8 vWD subjects when DDAVP was given by either the IV route or by IN spray. In their vWD type I subjects, Nilsson and Lethagen [24] found that the BT was equally reduced by IV or IN spray admin istration of DDAVP.…”

Section: Effectiveness Of Ddavp Given By In Spraysupporting

confidence: 73%

“…In their vWD type I subjects, Nilsson and Lethagen [24] found that the BT was equally reduced by IV or IN spray admin istration of DDAVP. There appears to be good reproducibility of results when DDAVP is given by IN spray to the same individual on different occasions, just as there is when the drug is given IV [24,29].…”

Section: Effectiveness Of Ddavp Given By In Spraymentioning

confidence: 99%

See 1 more Smart Citation

Response to 1-Deamino-8-<i>D</i>-Arginine Vasopressin in von Willebrand Disease

Lusher

1994

Pathophysiol Haemos Thromb

Self Cite

View full text Add to dashboard Cite

The synthetic agent, l-deamino-8-D-arginine vasopressin (DDAVP), is generally regarded to be the treatment of choice for persons with type I von Willebrand disease (vWD), and may be useful in type IIA vWD as well. Several formulations of the drug are available, including a highly concentrated intranasal spray formulation which is ideal for home use. The degree of F VIII and vWF response to DDAVP varies among individuals, but is generally consistent in individual patients over time. Some have tachyphylaxis while others do not. While side effects are uncommon, DDAVP is a potent antidiuretic agent. Thus one should be aware of the possibility of hyponatremia and water intoxication if certain precautions are not observed.

show abstract

Section: Effectiveness Of Ddavp Given By In Spraysupporting

confidence: 73%

Section: Effectiveness Of Ddavp Given By In Spraymentioning

confidence: 99%

Response to 1-Deamino-8-<i>D</i>-Arginine Vasopressin in von Willebrand Disease

Lusher

1994

Pathophysiol Haemos Thromb

Self Cite

View full text Add to dashboard Cite

show abstract

Transfusion Therapy in Congenital Coagulopathies

Lusher

1994

Hematology/Oncology Clinics of North America

View full text Add to dashboard Cite

The administration of desmopressin by nasal spray: a dose‐determination study in patients with mild haemophilia A or von Willebrand's disease

et al. 1995

View full text Add to dashboard Cite

Desmopressin is an important haemostatic agent in many types of bleeding disorders. The intranasal route for administration of desmopressin has attracted much interest because it is convenient and makes self-treatment possible. In the present study the effects of three doses (300, 450 and 600 μg) of desmopressin delivered by nasal spray and those of 0.3 μg/kg injected intravenously were compared in five patients with haemophilia A and 11 with von Willebrand's disease. There was no statistically significant difference in peak VIII:C concentration in the haemophilia patients and no difference in peak vWF concentration in von Willebrand patients between the four desmopressin dosages. Bleeding time response was comparable after all four dosages. We recommend a spray dosage of 300 μg for home treatment. As cover for major surgery or in connection with severe bleedings, however, intravenous administration is to be recommended.

show abstract

Use of a Highly Concentrated Intranasal Spray Formulation of Desmopressin in Persons with Congenital Bleeding Disorders

Cited by 3 publications

References 11 publications

Response to 1-Deamino-8-<i>D</i>-Arginine Vasopressin in von Willebrand Disease

Response to 1-Deamino-8-<i>D</i>-Arginine Vasopressin in von Willebrand Disease

Transfusion Therapy in Congenital Coagulopathies

The administration of desmopressin by nasal spray: a dose‐determination study in patients with mild haemophilia A or von Willebrand's disease

Contact Info

Product

Resources

About